Literature DB >> 11397301

The diagnosis and treatment of periorbital sarcoid in the horse: 445 cases from 1974 to 1999.

D.C. Knottenbelt1, D.F. Kelly.   

Abstract

OBJECTIVE: Diagnosis and management of periorbital sarcoids in horses is a significant clinical challenge for the practicing veterinary surgeon and pathologist. The purpose of this study was to investigate the response of various types of sarcoids to different therapeutic methods. Animals studied Medical records of 445 clinical patients. Procedures This paper retrospectively examines the clinical and histological features of periorbital sarcoids and the treatment of 445 cases. Treatment by surgical excision, cryosurgery, Bacillus-Calmette-Gaérin (BCG) immunomodulation, topical cytotoxic applications, and radiation are described.
RESULTS: Six types of sarcoid can be found in the immediate periorbital region and each has some characteristics of other disorders of the skin with which they can be confused. The diagnosis of sarcoids is, however, relatively simple in most cases. The lesions are not necessarily restricted to the dermis and epidermis, but commonly invade into the subcutis and the deeper muscular structures around the eye. Treatment with radiation is expensive and difficult to manage but resulted in the best outcome with almost 100% resolution in 66 cases. By contrast, surgical excision has serious potential complications that arise primarily as a result of the infiltrative nature of periorbital sarcoids. The value of BCG immunomodulation therapy for fibroblastic and nodular lesions described by previous workers is confirmed in this paper, with a good overall response (69%), provided that the material was injected intralesionally. Perilesional injection did not appear to carry a significant benefit. However, treatment of verrucose or occult lesions by this method gave generally poor results. The results of intralesional injection of cisplatin emulsions suggest that this may be an effective method of treatment in cases where other modalities are not feasible. In common with previous reports, failure to resolve the lesions frequently resulted in regrowth of the tumor, and in most cases this recurrence appeared to be more aggressive, with extensive local infiltration and faster growth. Conclusion The periorbital tissues are less tolerant of damage than those at many other sites and therefore certain treatment methods may be contraindicated. This suggests that it is important to select the best possible treatment at the first opportunity. It is a wise precaution to warn owners of horses with periorbital sarcoids of the dangers of leaving them and the particular risks associated with the currently available treatments.

Entities:  

Year:  2000        PMID: 11397301     DOI: 10.1046/j.1463-5224.2000.00119.x

Source DB:  PubMed          Journal:  Vet Ophthalmol        ISSN: 1463-5216            Impact factor:   1.644


  9 in total

1.  Periocular sarcoid with bone invasion in a Thoroughbred mare.

Authors:  Andres Giraldo; Chantale L Pinard; Brandon L Plattner; Marie-Soleil Dubois
Journal:  Can Vet J       Date:  2020-04       Impact factor: 1.008

2.  The potential of three whole blood microRNAs to predict outcome and monitor treatment response in sarcoid-bearing equids.

Authors:  E Hamza; J Cosandey; V Gerber; C Koch; L Unger
Journal:  Vet Res Commun       Date:  2022-04-28       Impact factor: 2.459

3.  Transcriptional changes induced by bovine papillomavirus type 1 in equine fibroblasts.

Authors:  Z Q Yuan; L Nicolson; B Marchetti; E A Gault; M S Campo; L Nasir
Journal:  J Virol       Date:  2008-04-23       Impact factor: 5.103

4.  Surgical Management of Penile and Preputial Neoplasms in Equine with Special Reference to Partial Phallectomy.

Authors:  Awad Rizk; Esam Mosbah; Gamal Karrouf; Mohamed Abou Alsoud
Journal:  J Vet Med       Date:  2013-09-08

5.  Equine sarcoid: In situ demonstration of matrix metalloproteinase expression.

Authors:  S Mosseri; U Hetzel; Shelley Hahn; Eleni Michaloupoulou; Hannah Clare Sallabank; Derek C Knottenbelt; A Kipar
Journal:  Vet J       Date:  2014-08-28       Impact factor: 2.688

6.  ALVAC-fIL2, a feline interleukin-2 immunomodulator, as a treatment for sarcoids in horses: A pilot study.

Authors:  Corey Saba; Randall Eggleston; Andrew Parks; John Peroni; Eric Sjoberg; Shelbe Rice; Jesse Tyma; Jarred Williams; Deborah Grosenbaugh; A Timothy Leard
Journal:  J Vet Intern Med       Date:  2022-04-13       Impact factor: 3.175

7.  Equine sarcoids: Bovine Papillomavirus type 1 transformed fibroblasts are sensitive to cisplatin and UVB induced apoptosis and show aberrant expression of p53.

Authors:  Margaret Finlay; Zhengqiang Yuan; Iain M Morgan; M Saveria Campo; Lubna Nasir
Journal:  Vet Res       Date:  2012-12-04       Impact factor: 3.683

8.  Diagnostic potential of three serum microRNAs as biomarkers for equine sarcoid disease in horses and donkeys.

Authors:  Lucia Unger; Carlos Abril; Vinzenz Gerber; Vidhya Jagannathan; Christoph Koch; Eman Hamza
Journal:  J Vet Intern Med       Date:  2021-01-07       Impact factor: 3.175

9.  Diagnostic and prognostic potential of eight whole blood microRNAs for equine sarcoid disease.

Authors:  Jeanne Cosandey; Eman Hamza; Vinzenz Gerber; Alessandra Ramseyer; Tosso Leeb; Vidhya Jagannathan; Klaudia Blaszczyk; Lucia Unger
Journal:  PLoS One       Date:  2021-12-23       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.